| Title: |
Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry |
| Authors: |
Marchesi, F.; Salmanton-García, J.; Buquicchio, C.; Itri, F.; Besson, C.; Dávila-Valls, J.; Martín-Pérez, S.; Fianchi, L.; Rahimli, L.; Tarantini, G.; Grifoni, F.I.; Sciume, M.; Labrador, J.; Cordoba, R.; López-García, A.; Fracchiolla, N.S.; Farina, F.; Ammatuna, E.; Cingolani, A.; García-Bordallo, D.; Gräfe, S.K.; Bilgin, Y.M.; Dargenio, M.; González-López, T.J.; Guidetti, A.; Lahmer, T.; Lavilla Rubira, Esperanza; Méndez, G.-A.; Prezioso, L.; Schönlein, M.; Van Doesum, J.; Wolf, D.; Hersby, D.S.; Magyari, F.; Van Praet, J.; Petzer, V.; Tascini, C.; Falces-Romero, I.; Glenthøj, A.; Cornely, O.A.; Pagano, L. |
| Publication Year: |
2023 |
| Subject Terms: |
Humans; COVID-19; SARS-CoV-2; Hematologic Neoplasms; Antibodies; Monoclonal; Immunization; Passive; Registries; AS Lugo; CHULA |
| Description: |
Only few studies have analyzed the efficacy of tixagevimab/cilgavimab to prevent severe Coronavirus disease 2019 (COVID-19) and related complications in hematologic malignancies (HM) patients. Here, we report cases of breakthrough COVID-19 after prophylactic tixagevimab/cilgavimab from the EPICOVIDEHA registry). We identified 47 patients that had received prophylaxis with tixagevimab/cilgavimab in the EPICOVIDEHA registry. Lymphoproliferative disorders (44/47, 93.6%) were the main underlying HM. SARS-CoV-2 strains were genotyped in 7 (14.9%) cases only, and all belonged to the omicron variant. Forty (85.1%) patients had received vaccinations prior to tixagevimab/cilgavimab, the majority of them with at least two doses. Eleven (23.4%) patients had a mild SARS-CoV-2 infection, 21 (44.7%) a moderate infection, while 8 (17.0%) had severe infection and 2 (4.3%) critical. Thirty-six (76.6%) patients were treated, either with monoclonal antibodies, antivirals, corticosteroids, or with combination schemes. Overall, 10 (21.3%) were admitted to a hospital. Among these, two (4.3%) were transferred to intensive care unit and one (2.1%) of them died. Our data seem to show that the use of tixagevimab/cilgavimab may lead to a COVID-19 severity reduction in HM patients; however, further studies should incorporate further HM patients to confirm the best drug administration strategies in immunocompromised patients. ; EPICOVIDEHA has received funds from Optics COMMIT (COVID-19 Unmet Medical Needs and Associated Research Extension) COVID-19 RFP program by GILEAD Science, United States (Project 2020-8223) |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
GILEAD Science, United States [2020-8223]; https://doi.org/10.1186/s13045-023-01423-7; https://portalcientifico.sergas.gal//documentos/643af6a51656ab66db7e0700; https://hdl.handle.net/20.500.11940/21833; 643af6a51656ab66db7e0700 |
| DOI: |
10.1186/s13045-023-01423-7 |
| Availability: |
https://hdl.handle.net/20.500.11940/21833; https://portalcientifico.sergas.gal//documentos/643af6a51656ab66db7e0700; https://doi.org/10.1186/s13045-023-01423-7 |
| Rights: |
Attribution 4.0 International (CC BY 4.0) ; http://creativecommons.org/licenses/by/4.0/ ; openAccess |
| Accession Number: |
edsbas.D5204707 |
| Database: |
BASE |